Compare Rybrevant vs. Tagrisso
Head-to-head comparisons of medication uses, side effects, warnings, and more.
Key takeaways
Rybrevant (amivantamab) and Tagrisso (osimertinib) are both medications used to treat non-small cell lung cancer (NSCLC) with specific mutations in the epidermal growth factor receptor (EGFR) gene. However, they belong to different medication classes and have distinct characteristics. Rybrevant is a bispecific antibody that targets both EGFR and MET proteins, and it is administered intravenously. It is used in combination with other medications or alone, depending on the treatment stage. Common side effects include infusion-related reactions, rash, and skin infections. Tagrisso, on the other hand, is an oral EGFR inhibitor that specifically targets mutated EGFR proteins. It is taken once daily and is known for causing an acne-like rash and diarrhea. Tagrisso can be used as an initial treatment or when other EGFR inhibitors are no longer effective. Both medications are not recommended during pregnancy.
- Rybrevant (amivantamab)Tagrisso (osimertinib)
- Rybrevant (amivantamab)Tagrisso (osimertinib)
Summary of Rybrevant vs. Tagrisso
Summary for Bispecific EGF receptor-directed and MET receptor-directed antibodyPrescription onlyRybrevant (amivantamab-vmjw) is an injectable medication used for adults with non-small cell lung cancer (NSCLC) with certain mutations in the epidermal growth factor receptor (EGFR) gene. The medication is given as an intravenous infusion through your vein (IV), and how often you receive it depends on what you’re being treated for. You also might receive it with other cancer medications. Some common side effects of Rybrevant (amivantamab) include infusion-related reactions, rash, feeling tired, and infected skin around the nail.
Summary for EGFR inhibitorPrescription onlyTagrisso (osimertinib) is a prescription tablet used to treat adults with certain types of non-small-cell lung cancer (NSCLC) with a specific mutation in the EGFR gene. It’s FDA approved for use in early-stage cases after surgery, as well as in advanced and metastatic stages. This medication is an EGFR inhibitor that helps slow the growth and spread of cancer cells. It’s typically taken once a day by mouth, with or without food. Common side effects include low blood cell counts, diarrhea, and rash.
Indications of Rybrevant vs. Tagrisso
Indications forAdults with locally advanced or metastatic NSCLC with certain EGFR mutations:
•In combination with lazertinib as a first-choice treatment•In combination with carboplatin and pemetrexed as a second-choice treatment for those whose condition has worsened or didn't respond well to EGFR tyrosine kinase inhibitor•Given alone for those whose condition has worsened or didn’t respond well to platinum-based chemotherapyIndications forNon-small-cell lung cancer (NSCLC) in adults with specific EGFR mutations, including:
•Early-stage NSCLC after surgery to remove the tumor•Advanced NSCLC that can’t be removed by surgery, if the cancer hasn’t gotten worse with platinum-based chemotherapy and radiation therapy•Metastatic NSCLC as the first treatment•Advanced or metastatic NSCLC as a first treatment taken together with pemetrexed and platinum-based chemotherapy•Metastatic NSCLC that’s longer responding to other EGFR inhibitorsPros and Cons of Rybrevant vs. Tagrisso
Pros and Const for Bispecific EGF receptor-directed and MET receptor-directed antibodyPros•Recommended option for non-small cell lung cancer (NSCLC) in certain adults•Works in a more targeted way than traditional chemotherapy•Lasts a long time in the body, so it doesn’t need to be taken every dayCons•Commonly causes rash, infected skin around the nails, and serious infusion-related reactions•Needs to be infused through the vein at an infusion center or clinic•Long infusion times, especially for the first few treatmentsPros and Const for EGFR inhibitorPros•Oral tablet taken once a day•Can be used to treat early and advanced stages of NSCLC•Works in a more specific, targeted way than traditional chemotherapyCons•Requires EGFR testing before use•Can cause skin and stomach-related side effects•Not recommended during pregnancy or breastfeedingCommon Side Effects of Rybrevant vs. Tagrisso
Common Side Effects for•Rash•Infected skin around the nail•Muscle and joint pain•Sores in the mouth•Swelling of hands, ankles, feet, face, or all of your body•Unusual feeling in the skin (such as tingling or a crawling feeling)•Feeling very tired•Diarrhea•Constipation•COVID-19•Dry skin•Bleeding•Decreased appetite•Itchy skin•Nausea•Changes in certain blood tests•Vomiting•Shortness of breath•CoughNote: The side effects listed above reflect reports from clinical studies where Rybrevant (amivantamab) was given alone or with other medications.
Common Side Effects for•Low white blood cell count (up to 65%)•Low platelet count (53%)•Low red blood cell count (52%)•Diarrhea (47%)•Skin rash (46%)•Muscle pain (38%)•Nail changes (34%)•Dry skin (32%)•Mouth sores (24%)•Tiredness (21%)Warnings of Rybrevant vs. Tagrisso
Common Side Effects for•Infusion-related reactions•Lung problems•Blood clots (if used in combination with lazertinib)•Skin problems•Eye problems•Harm to the unborn babyCommon Side Effects for•Lung problems•Heart rhythm problem (QT prolongation)•Heart problems•Eye problems•Skin problems•Inflammation of the blood vessels in your skin•Blood and bone marrow problems•Harm to unborn babyPrices with our coupons for Rybrevant vs. Tagrisso
Browse medications
View AllResearch prescriptions and over-the-counter medications from A to Z, compare drug prices, and start saving.